| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, California 94080
1 To whom requests for reprints should be addressed, at Preclinical Research and Exploratory Development, SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080. Phone: (650) 837-3655; Fax: (650) 837-3308; E-mail: tinya-abrams{at}sugen.com
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The molecular abnormalities underlying SCLC are not well understood. One feature of SCLC is coexpression of the KIT RTK with its ligand, SCF, in up to 70% of SCLC cell lines and clinical SCLC samples. SCF-stimulated KIT signaling has been most extensively studied in its role of regulating proliferation and survival of hematopoietic progenitor cells (3). However, KIT activation has also been shown to stimulate proliferation of SCLC-derived cell lines in culture (4), and dysregulated KIT activation has been implicated in driving some tumors; for example, activating mutations of KIT have been identified in gastrointestinal stromal tumors (5, 6), acute myeloid leukemia, and some cases of mastocytosis (7). Whereas activating KIT mutations have not been observed in SCLC, the coexpression of KIT and SCF in SCLC suggests that an autocrine activation loop may result in elevated or prolonged KIT signaling in this malignancy and that interrupting this signaling pathway may provide a novel therapeutic approach to treat this devastating disease. As evidence for KIT signaling effects on growth in SCLC, stable transfection of KIT in a SCLC line that naturally produced SCF led to autocrine growth stimulation (4). In addition, expression of a kinase-defective form of KIT in a cell line that naturally coexpresses ligand and receptor led to a marked decrease in the ability of the cells to grow under growth factor-free conditions (4). Several KIT inhibitors have also been shown to block SCF-stimulated SCLC proliferation in vitro (8–11). However, the role of KIT activity in SCLC in vivo is not known.
The intention of these studies was to evaluate the activity of the indolinone kinase inhibitor SU11248 against KIT in vitro and in vivo and to model the utility of SU11248 for the treatment of SCLC. SU11248 is a selective, oral, multitargeted RTK kinase inhibitor of PDGFR, VEGFR, and FLT3 with 5–50 n
IC50 values in cellular autophosphorylation assays (12, 13). SU11248 was also designed to target KIT and was expected to inhibit KIT kinase activity in cells.
SU11248 has shown antitumor activity by inhibiting both RTKs expressed by tumor cells and involved in tumor proliferation and survival and RTKs expressed on endothelial or stromal cells. As an example of the former, SU11248 blocks the activity of wild-type and activated FLT3 expressed by acute myelogenous leukemia-derived cell lines (13). The latter mechanism of inhibition is supported by the fact that SU11248 also inhibits the VEGFR FLK/KDR and PDGFRß, both of which play a prominent role in angiogenesis (14).
As a comparator KIT inhibitor in the in vivo studies, the aminopyrimidine STI571 (imatinib mesylate, Gleevec; Novartis Pharmaceuticals, East Hanover, NJ), a structurally distinct tyrosine kinase inhibitor, was used. STI571, like SU11248, inhibits both KIT and PDGFR, but with an IC50 of 
100 n in cellular assays (15, 16). STI571 is an effective inhibitor of KIT autophosphorylation and SCF-stimulated proliferation in SCLC cellular assays (10).
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cells were cultured using standard technique in RPMI 1640 supplemented with 10% FBS, 2 m glutamine, and 1 m sodium pyruvate (Life Technologies, Inc., Gaithersburg, MD) and maintained routinely in a humidified chamber at 37°C and 5% carbon dioxide. When grown under conditions for serum deprivation, 0.1% FBS (Life Technologies, Inc.) was added to the medium.
IP/W Analysis in Vitro.
NCI-H526 cells were starved in low serum (0.1% FBS) overnight before treatment with SU11248 for 2 h. After compound treatment, cells were stimulated with 250 ng/ml recombinant human SCF or 20 ng/ml IGF-I (R&D Systems, Minneapolis, MN) for 15 min. Cells were then lysed with HNTG lysis buffer (50 m HEPES, 150 m NaCl, 10% glycerol, 1% Triton X-100, 1.5 m MgCl2,, and 1 m EGTA) containing protease and phosphatase inhibitors [10 m sodium fluoride, 1 m sodium orthovanadate, 1 m Pefabloc (Roche Molecular Biochemicals); 2 m bestatin, 280 µ E-64, 200 µ leupeptin, 200 µ pepstatin A, and 60 µ aprotinin], and protein concentration in lysates was determined using the BCA assay kit according to the manufacturer’s instructions (Pierce, Rockford, IL). One mg of protein from each sample was immunoprecipitated overnight at 4°C with an anti-KIT antibody (SC-1493; Santa Cruz Biotechnology, Santa Cruz, CA) and protein G-agarose beads (16-266; Upstate Biotechnology, Lake Placid, NY). Immune complexes were washed with HNTG lysis buffer containing inhibitors. Proteins were eluted by boiling in SDS sample buffer, separated by SDS-PAGE, and transferred to nitrocellulose membranes. Membranes were probed with an anti-phosphotyrosine antibody (SC-7020; Santa Cruz Biotechnology) and then stripped with Restore Western Blot Stripping Buffer (Pierce). To detect total KIT levels, membranes were reprobed with the same anti-KIT antibody that was used for the immunoprecipitation. Lysates were also immunoprecipitated with an anti-IGF-IR antibody (SC-713; Santa Cruz Biotechnology), and Western blot analysis was performed using antibodies against phosphotyrosine (SC-7020; Santa Cruz Biotechnology) or total IGF-IR, as described above. Western blot analysis of ERK1/2 (Thr 202/Tyr 204; 9106; Cell Signaling, Beverly, MA) was performed on whole cell lysates (40 µg) as described above.
Cell Proliferation Assay.
NCI-H526 cells were starved in low serum overnight in a medium containing 0.1% FBS. Cells were plated in 96-well plates at a density of 1 x 104 cells/well and treated for 30 min with SU11248 before ligand stimulation. Subsequently, cells were stimulated for 15 min with 100 ng/ml recombinant human SCF or 20 ng/ml IGF-I (R&D Systems) and cultured continuously in the presence of SU11248. After 72 h, cellular metabolism was assessed using the XTT colorimetric dye reduction method (1465015; Roche Molecular Biochemicals). XTT assays were also performed on NCI-H526 cells growing in 10% FBS.
Apoptosis Assay.
NCI-H526 cells were cultured in low serum (0.1% FBS) overnight. A total of 5 x 104 cells/well were treated with SU11248 for 30 min before the addition of ligand and then stimulated with 100 ng/ml recombinant human SCF. Cells were incubated for 24 h at 37°C. Then cells were pelleted by centrifugation (1500 rpm for 5 min), washed in 1 ml of culture medium, and pelleted again. Cell pellets were processed according to the manufacturer’s protocol using the Cell Death Detection ELISA KIT (Roche Molecular Biochemicals) for determination of histone-associated DNA fragments.
In Vivo Implantation of SCLC and Efficacy Studies.
Cells to be implanted in mice were harvested from cell culture flasks during exponential growth, washed once with sterile PBS, counted, and resuspended in PBS to a suitable concentration before implantation.
All animal studies were carried out with the approval of the SUGEN Institutional Animal Care and Use Committee in an American Association for Accreditation of Laboratory Animal Care (AAALAC)-accredited vivarium and in accordance with the Institute of Laboratory Animal Research (Guide for the Care and Use of Laboratory Animals, NIH, Bethesda, MD). Female 9–12-week-old athymic nu/nu mice purchased from Charles River Laboratories (Wilmington, MA) were used.
Mice received s.c. injections into the hind flank on day 0 with 5 x 106 NCI-H526 or NCI-H82 cells. Animals with established tumors (approximately 300–500 mm3) were randomized into treatment groups of 10 mice each for efficacy studies. SU11248, STI571, or their vehicle was administered as indicated in the figure legends. SU11248 and STI571 were delivered p.o. in a carboxymethylcellulose suspension by gavage. Tumor growth was measured twice weekly using Vernier calipers for the duration of the treatment. Tumor volumes were calculated as the product of length x width x height. For all studies, P values were calculated using the two-tailed Student’s t test.
Combination Treatment of SU11248 and Cisplatin against NCI-H526 SCLC Tumors.
Mice bearing s.c. tumors established to 250–300 mm3 in volume were treated either p.o. once daily with SU11248 to the end of the study, i.p. once daily with cisplatin for the first 5 days, or a combination of the two. Cisplatin was prepared in 0.9% saline. Compounds or their vehicles were administered as indicated in the figure legends. Tumor growth was measured twice weekly using Vernier calipers for the duration of the treatment. Tumor volumes were calculated as the product of length x width x height. For all studies, Ps were calculated using the two-tailed Student’s t test.
In Vivo Target Modulation Studies in NCI-H526 SCLC Tumors.
At the end of the efficacy studies evaluating the effects of SU11248 and STI571 on NCI-H526 tumor volume, mice bearing tumors were treated with a final oral dose of SU11248 or STI571 at the indicated concentrations. Control animals received an oral dose of vehicle. Four h after SU11248 treatment and 2 h after STI571 treatment (Cmax), individual mice were euthanized, and tumors were resected. The resected tumors were immediately pulverized using a liquid nitrogen-cooled cryomortar and pestle and stored at -70°C until use. Pulverized tumors were later homogenized in cold HNTG lysis buffer with protease and phosphatase inhibitors (see "IP/W Analysis in Vitro"). The lysates were centrifuged at 14,000 rpm for 25 min at 4°C. The resulting supernatant was collected, and the amount of protein in each lysate was immediately determined using the BCA Protein Assay (Pierce). One mg of lysate from each sample was then immunoprecipitated overnight at 4°C using an agarose-conjugated antibody to KIT (SC-1493AC; Santa Cruz Biotechnology) or PDGFRß (06-498; Upstate Biotechnology). Immunoprecipitated protein was resolved by SDS-PAGE and electrotransferred onto a nitrocellulose membrane. The membrane was then blocked for 1 h at room temperature in 5% nonfat milk in TBST [1 m Tris (pH 7.4), 150 m NaCl, and 1% Triton X-100]. The amount of phosphorylated KIT in each sample was determined by probing the membranes with an antibody to phosphotyrosine (UBI4G10; Upstate Biotechnology) overnight at 4°C; for the analysis of total KIT or PDGFR, the blots were stripped, reblocked, and reprobed with an antibody to KIT (A-4542; DAKO Corp., Carpinteria, CA) or PDGFRß (SC-432; Santa Cruz Biotechnology) overnight at 4°C. After washing, the membranes were incubated with either antimouse or antirabbit horseradish peroxidase-conjugated antibodies (Amersham Pharmacia Biotech, Piscataway, NJ) for 2 h at room temperature, washed again, and developed by the enhanced chemiluminescence method according to the manufacturer’s instructions (ECL; Amersham Pharmacia Biotech).
KIT and PDGFRß Immunohistochemistry.
Sections were prepared from formalin-fixed, paraffin-embedded s.c. tumors. For detection of KIT, a rabbit polyclonal antihuman antibody (A-4502; DAKO Corp.) and horseradish peroxidase enzyme-labeled polymer conjugated to polyclonal rabbit secondary antibodies (EnVision+ Systems; DAKO Corp.) were used. For PDGFRß detection, a rabbit polyclonal antibody (SC-432; Santa Cruz Biotechnology) and a biotinylated goat antirabbit secondary antibody (Vector Laboratories, Burlingame, CA), followed by a peroxidase-based immunostaining protocol (Vectastain ABC Elite KIT; Vector Laboratories), were used. In both cases, peroxidase enzyme was developed with 3,3'-diaminobenzidine as a substrate.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. To examine the effect of SU11248 treatment on a SCF-mediated signaling event downstream of KIT activation, ERK1/2 phosphorylation was investigated. As shown in Fig. 1, SU11248 also inhibited SCF-stimulated ERK1/2 phosphorylation in a dose-dependent manner, with an IC50 value consistent with that for inhibition of KIT phosphotyrosine levels. NCI-H526 cells also express IGF-IR, which is not a target of SU11248. To demonstrate compound selectivity in NCI-H526 cells, SU11248 did not significantly inhibit IGF-IR phosphotyrosine levels up to 1 µ, as monitored by IP/W analysis (Fig. 1).
|
. Concentrations of SU11248 below 0.1 µ did not result in absorbance readings below the level of the untreated control cells, suggesting that at these drug concentrations, inhibition of proliferation occurred without a cytotoxic response. Additionally, an ELISA assay detecting histone-associated DNA fragments revealed that apoptosis occurred at doses higher than those required to inhibit SCF-induced proliferation. In contrast, SU11248 did not inhibit IGF-I-stimulated proliferation of NCI-H526 cells.
|
1 µ SU11248. At higher concentrations, dose-dependent growth inhibition was observed.
|
Tumor volumes were measured and compared with tumors from animals that received drug vehicle alone. Fig. 4A shows that SU11248 p.o. administered at 40 and 80 mg/kg/day had significant in vivo activity against the NCI-H526 human SCLC tumor xenograft, resulting in inhibition of growth [day 36, 57% inhibition (P = 0.001) and 74% inhibition (P = 0.0002), respectively]. STI571 p.o. administered twice daily at 160 mg/kg also demonstrated efficacy, exhibiting up to 35% inhibition (P = 0.04) on day 31. In Fig. 4B, SU11248 administered at 40 and 80 mg/kg/day also significantly inhibited the KIT-negative NCI-H82 SCLC tumor model [day 39, 46% inhibition (P = 0.05) and 75% inhibition (P = 0.0013), respectively]. STI571 had no effect on tumor growth in this model.
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Activating mutations in KIT have been implicated in a number of neoplasias, in particular gastrointestinal stromal tumors, adult-onset mastocytosis, and acute myelogenous leukemia (5, 6). The extent to which growth and survival of these diseases rely on KIT signaling remains to be determined. However, exploitation of the anti-KIT activity of STI571 (Gleevec) resulted in objective responses in patients with gastrointestinal stromal tumors, and Gleevec is now approved for this indication. KIT activity has also been implicated in regulating the proliferation in vitro of cell lines derived from human SCLC through autocrine and/or paracrine stimulation of the receptor by its ligand (4). This, together with data on frequent KIT overexpression in human SCLC (22–25), at times associated with SCF coexpression (22–24), suggests that blocking the function of KIT may be a useful therapeutic approach for SCLC.
Using the KIT-positive NCI-H526 SCLC cell line, we demonstrated that SU11248 inhibited SCF-dependent KIT phosphorylation, signal transduction, and cell proliferation in vitro. In the presence of complete serum, the IC50 value for inhibition of proliferation was much higher than that for SCF-stimulated proliferation, as reported previously for STI571 (22–24). This is likely due to the contribution of multiple growth factors in serum stimulating multiple signaling pathways including those not inhibited by SU11248 at submicromolar concentrations.
KIT signaling has been shown to be important for survival in hematopoietic cells (26). However, we found no effect of SU11248 on apoptosis in SCF-stimulated cultured cells at levels that block KIT activity. SCLC tumor-derived cells may be less dependent on KIT signaling for survival than are hematopoietic cells. Many tumor-derived lines secrete autocrine growth factors, some of which are likely to maintain survival in the absence of serum (27).
Consistent with the cytostatic nature of the drug in vitro against this cell line, SU11248 treatment significantly inhibited the growth of established s.c. KIT-expressing tumors in athymic mice, but it did not induce tumor regression. As a comparator in the in vivo studies, we used the structurally distinct aminopyrimidine tyrosine kinase inhibitor STI571 (Gleevec), known to inhibit KIT as well as Bcr-Abl and PDGFR (15, 16). STI571 is an effective inhibitor of KIT autophosphorylation and SCF-stimulated proliferation in SCLC cellular assays (10). In these efficacy studies, STI571 moderately inhibited tumor growth of NCI-H526.
These findings led to an evaluation of KIT phosphotyrosine levels in NCI-H526 tumor samples collected at the end of the efficacy studies. As predicted from in vitro assays, KIT phosphotyrosine levels were reduced by SU11248 in established SCLC tumors in a dose-dependent manner. STI571 partially reduced KIT phosphotyrosine levels in the these tumors, although it was less effective than SU11248 at the doses used in this study, consistent with the relative activities in vitro and lower degree of efficacy against NCI-H526 tumor growth.
The marked tumor growth inhibition of the KIT-negative SCLC line NCI-H82 by SU11248 prompted an IHC evaluation of tumor xenograft sections for the expression of the angiogenic receptor PDGFRß, another SU11248 target, expressed on pericytes surrounding endothelial cells and fibroblasts. PDGFRß expression was identified in the supporting stroma of tumors derived from these SCLC lines. Furthermore, PDGFRß phosphorylation was completely suppressed in SU11248-treated NCI-H526 tumor samples even at the lower dose used in this study. As observed with inhibition of KIT phosphotyrosine levels, STI571 partially reduced PDGFRß phosphotyrosine levels in the NCI-H526 tumors. This may be due to the lower potency of STI571 against KIT and PDGFR and/or to pharmacokinetic properties in mice that prohibit tumor exposure sufficient to suppress the molecular targets of STI571. Additionally, the inhibitory target profile of SU11248 is different from that of STI571, and inhibition of SU11248 targets not affected by STI571, such as the VEGFR FLK1/KDR, may contribute to growth suppression.
Whereas SU11248 has been shown to inhibit targets expressed by tumor cells, as well as targets expressed in the supporting stromal cells (12), several factors suggest that the efficacy of SU11248 in these SCLC preclinical models may be conferred in part by targeting PDGFR and the VEGFR FLK1/KDR. First, SU11248 inhibits tumor growth at drug exposures that fully inhibit PDGFR while only partially suppressing KIT activity. PDGFR signaling on the pericytes supporting tumor vasculature is known to contribute to the process of neovascularization in growing tumors (14), as does FLK1/KDR signaling in endothelial cells (28, 29). Second, SU11248 has previously been demonstrated to inhibit FLK1/KDR phosphorylation in vivo and was similarly found to inhibit VEGF-induced vascular permeability in mice (12). VEGF expression and serum levels of VEGF have been found to be associated with poor prognosis (30–32) and shorter survival in SCLC patients (30). Although we have not examined the contribution of FLK1/KDR in these SCLC-derived tumors, it is a target of SU11248 that is likely contributing to the inhibition observed by SU11248 in this study.
The advent of molecular targeted oncology therapies offers the opportunity to selectively inhibit key molecular defects in human cancers and tailor therapies to distinct tumor types. The challenge in developing such therapies is to understand the relative contributions of different molecular defects to tumor growth, survival, and metastasis. In SCLC, KIT signaling has been implicated in pathogenesis based on KIT overexpression and coexpression of its ligand, SCF, in a majority of tumors.
We found that SU11248 inhibited KIT activity in SCLC-derived tumor xenografts and also inhibited tumor growth but was equally efficacious in blocking the growth of KIT-negative tumors. Thus, although KIT overexpression is common in SCLC tumors, it is unclear whether KIT is a major factor in driving the growth of SCLC, and it has yet to be established in the clinic that inhibition of wild-type KIT activity in a tumor will have an impact on that cancer.
The advantage of using multitargeted inhibitors is the opportunity to block tumor growth by multiple mechanisms. Despite the unclear role for KIT activity in these SCLC tumor xenografts, KIT signaling may contribute to clinical cases of the disease. SU11248 offers a potential novel therapy for this disease because beyond providing direct antitumor activity, SU11248 could provide additional significant benefit in the clinic via inhibition of PDGFRß and FLK1/KDR in tissues supporting the cancer (12). In addition, we have shown that SU11248 in combination with cisplatin, the standard of care for first-line therapy in SCLC, was well tolerated and caused a significant delay in tumor regrowth compared with either agent alone. Small molecule inhibitors that target several distinct molecular targets regulating both tumor cell growth and survival directly and the supporting stroma of the tumor may provide the greatest impact in the clinic.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Received 12/30/02; revised 2/13/03; accepted 2/21/03.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Bunn Jr Diseases Desperate Grown J Natl Cancer Inst, April 16, 2008; 100(8): 520 - 521. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, R. Govindan, J. N. Atkins, H. H. Gillenwater, C. Pallares, et al. Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2008; 26(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al. Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P. G. Casali, P. Beck-Peccoz, and L. Fugazzola A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3531 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows Haematologica, May 1, 2007; 92(5): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giaccone The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Q.M. Chow and S. G. Eckhardt Sunitinib: From Rational Design to Clinical Efficacy J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther., July 1, 2006; 5(7): 1774 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Motzer, B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, June 7, 2006; 295(21): 2516 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ciomei, V. Croci, A. Ciavolella, D. Ballinari, and E. Pesenti Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin. Cancer Res., May 1, 2006; 12(9): 2856 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schoffski, A. Van Oosterom, P. Marynen, and M. Debiec-Rychter Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate Clin. Cancer Res., April 15, 2006; 12(8): 2622 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Albert, P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R.-Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., April 1, 2006; 5(4): 995 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, |
) or 20 ng/ml IGF-I (•). The number of metabolically active cells present after 72 h was determined by XTT assay. Data are presented as the percentage change in cell number during drug treatment relative to DMSO control and represent mean values obtained from three to four independent experiments. For apoptosis induction, NCI-H526 cells were incubated for 24 h with the indicated concentrations of SU11248 in serum-free medium plus SCF and then analyzed by ELISA for apoptotic cells. Data are expressed as the percentage of apoptotic cells relative to DMSO vehicle control (
).
) at 160 mg/kg/twice daily, or vehicle (
